In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus

Inclusion criteria: * Subjects must have type 2 diabetes mellitus that has been diagnosed for at least three months. * Must be taking either (1) no medication for their diabetes or (2) taking metformin, a sulfonylurea, or metformin and a sulfonylurea. * Subjects must be willing to wash-out of these medications for 14 days prior to the start of the study. * Subjects must have a BMII between 25 and 40 kg/m² and weigh at leas 50kg. * Women must be of non-childbearing potential. Exclusion criteria: * Laboratory values that meet certain criteria (for example, total cholesterol \> 240 mg/dL). * Clinically significant hepatic enzyme elevation. * Fasting plasma glucose greater than 240mg/dL. * Positive test result for Hepatitis B surface antigen, positive Hepatitis C or HIV. * Any major illness other than diabetes. * Previous use of insulin as treatment for diabetes. * Significant renal disease as defined by screening lab tests. * History of drug or other allergy, which in the opinion of the investigator contradicts subject participation. * Smoking or use of nicotine-containing products within the previous 6 months. * History of alcohol or drug abuse. * Unwilling to abstain from alcohol during the study. * Unwilling to abstain from caffeine- or xanthine-containing products during the study. * Use of St. John's Wort during the study. * Has donated 500 nL or more blood within 56 days of dosing or plans to donate blood in the month following study participation. * Previously received any GLP-1 mimetic that has moe than 70% sequence homology to GLP-1.